BUD

(redirected from budesonide)
Also found in: Dictionary, Medical, Wikipedia.
AcronymDefinition
BUDBudget
BUDBudweiser (US beer)
BUDBudesonide
BUDBig Ugly Dish
BUDBig Ugly Dog
BUDBusiness Unit Director
BUDBudapest, Hungary - Ferihegy (Airport Code)
BUDBuffer of Uniform Data
BUDBig Ugly Dude
BUDBargaining Unit Designator
BUDButt Ugly Development
BUDBig Ugly Dumb
BUDBerkshire Unitary District (UK)
BUDBenefits and Use Division (EPA)
BUDBackup Dissemination
References in periodicals archive ?
It is mainly used for the treatment of non-Budesonide glucocorticoid dependent or glucocorticoid Budesonide dependent bronchial asthma and chronic obstructive pulmonary disease (COPD).
As the study progressed, the children who took the budesonide remained one-half inch shorter through adulthood than the children who did not use the drug, said Strunk, who treats children with asthma at St.
From a clinical practice perspective, it would seem justified to recommend the budesonide 9-mg once-daily regimen, since this would be expected to improve adherence," said Dr.
She received inhaled budesonide for recurrent cough and bronchodilator-responsive wheeze and was later prescribed intranasal budesonide for allergic rhinitis.
Budesonide is an especially good choice for pregnant women who require high doses of inhaled steroids because it maximizes adherence, minimizes the need for systemic steroids, and has limited systemic effects.
The efficacy end points have previously been reported: Budesonide proved as effective as, and was better tolerated than, prednisolone and is now approved by the Food and Drug Administration as a first-line treatment for mild to moderate Crohn's disease.
COlonic RElease budesonide for the treatment of mild to moderate ulcerative colitis
In June 1997, budesonide aerosol got FDA's approval.
They compared the safety and efficacy of the budesonide combination with the standard therapy of prednisone with azathioprine.
During the study, Sachanandani assessed the effects of budesonide on adrenal function in nine patients between 2005 and 2006.
The company focuses on developing inhalation drugs including Unit Dose Budesonide (UDB), which treats pediatric asthma in children from six months to eights years of age.
This bronchoconstriction was significantly reduced (% inhibition) after pretreatment with the glucocorticosteroid budesonide (49%), the [[beta].